Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 16, 2023; 11(23): 5447-5454
Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5447
Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5447
Efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate COX regression analysis
Ding-Ran Wang, Department of Obstetrics and Gynaecology, Peking University Third Hospital, Beijing 100191, China
Author contributions: Wang DR designed the research study, performed the research, analyzed the data, wrote the manuscript, and read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Peking University Third Hospital Department of Obstetrics and Gynaecology.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There is no interest relationship.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ding-Ran Wang, PhD, Attending Doctor, Department of Obstetrics and Gynaecology, Peking University Third Hospital, No. 49 Huayuan North Road, Haidian District, Beijing 100191, China. ydausidb@163.com
Received: May 24, 2023
Peer-review started: May 24, 2023
First decision: June 12, 2023
Revised: June 15, 2023
Accepted: July 18, 2023
Article in press: July 18, 2023
Published online: August 16, 2023
Peer-review started: May 24, 2023
First decision: June 12, 2023
Revised: June 15, 2023
Accepted: July 18, 2023
Article in press: July 18, 2023
Published online: August 16, 2023
Core Tip
Core Tip: Adjuvant treatment with medroxyprogesterone acetate may have potential long-term prognostic benefits for patients with early-stage high-risk endometrial cancer. Age, pathological type, molecular typing, and myometrial infiltration were identified as relevant factors affecting patient prognosis.